LAVAL, QC, May 30, 2013 /CNW Telbec/ - Ergoresearch Ltd (TSXV: ERG) - based in Laval and chiefly known under the Clinique du
pied Équilibre, Orthoconcept and now Laboratoire Langelier banners -
announced today its third quarter results for the period ending March
31 2013. All figures quoted are in Canadian dollars.

Fiscal 2013 third quarter sales totalled $3,813,863, a 96.0% increase
compared to the same period in 2012, at $1,946,218. Increased sales
were primarily due to the following factors:

Influx of new products acquired through Laboratoire Langelier and
Laboratoire Podotech, in the amount of $1,318,173;

21.7% increase in regular product sales derived from the Company's own
technologies.

A 321% increase in operating income is reported in the third quarter of
fiscal 2013, or $399,871 compared to $94,951 for the third quarter of
fiscal 2012. Of note is that acquisition-based transaction fees
(non-recurring charges) resulted in a lowering of the operating income
numbers by $114,807 in the third quarter of fiscal 2013.

Company net profits reached $213,418 (5.6% of sales) in the quarter
compared to $71,149 (3.7% of sales) in the third quarter of fiscal
2012. Higher profitability is chiefly owed to a broader range of foot
orthotic and specialty orthotic products, including the OdrA, a new
product launched last October.

Ergoresearch and its subsidiaries are therefore pursuing their objective
of sustained growth, the outcome of a carefully executed business
strategy. "The launch of the patented OdrA orthotic device, under an
exclusive Canadian distribution licensing agreement, was well received
among both patients and the medical community," stated Sylvain Boucher,
President and CEO of Ergoresearch. "Given the Company's excellent
performance since the beginning of the year and with the recent
acquisitions of Podotech, Victhom human bionics and Laboratoire
Langelier which alone generated $6.5M in revenues for the 12-month
period ending this past December 31, the outlook for the future is
positive."

About ErgoresearchErgoresearch has developed the most important network of orthotics clinics in
Québec, with over one hundred clinics and satellite centres flying
under the banners of Clinique du pied Équilibre, Orthoconcept and Langelier Orthèses Chaussures. Québec's leading manufacturer of "intelligent" foot orthotics and
specialty orthotics, the company is a trend-setter in creating durable
medical equipment and software for the orthopedics market. Through its
subsidiary Victhom Human Bionics, it now also owns patents in the field of bionics, including
intellectual property for the Power Knee, the world's only motor-powered prosthesis with artificial intelligence
designed for above-knee amputees.

Ergoresearch has also developed and commercialized WebFit™, the first robotized custom-fit orthotics manufacturing software
program of its kind, launched the first Living Lab in Canada for knee osteoarthritis and more recently, a new
world-patented orthotic device called the OdrA, that revolutionizes the treatment of pain associated with knee OA.
Ergoresearch Ltd is listed on the TSX Venture Exchange (TSXV) under the
symbol ERG.

This is not an invitation to purchase securities listed on TSX Venture
Exchange. TMX Group and its affiliates do not endorse or recommend any
of the referenced securities or investment advisors. Please seek
professional advice to evaluate specific securities.

Forward looking statements
Certain statements in this Press Release contain forward-looking
statements and information that may entail certain risks related to
uncertainties. Such statements are based on management's expectations
and no assurance can be given that potential future results or
circumstances described in the forward looking statements will be
achieved or will occur. Such risks factors include, but are not limited
to, those related to the Corporation's ability to finance its
activities, competition, ability to negotiate and maintain
partnerships, the market acceptance of the said product, fluctuations
in operating results, the impact of general economics, industry and
market conditions, the ability to recruit and retain qualified
employees, the success of research and development programs,
fluctuations in cash flow, expectations regarding market demand for
particular products, the strength of intellectual property, market
dependence on new product development, the trust invested in
sub-contractors or their core personnel, as well as other documents
containing risks and uncertainties which are put forth every now and
then by the firm to various Canadian securities and exchange
commissions and made available at www.sedar.com.

The reader should not give great importance to forward-looking
statements as the results may differ from conclusions, predictions or
projections contained in such forward-looking statements; and certain
important factors or hypothesis taken into account in reaching
conclusions or the preparation of a projection or prediction may prove
to be incorrect in fact.

Management disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information,
future events or circumstances. All figures are in Canadian dollars,
unless otherwise specified.

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.